2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 393

From Childhood to Adulthood: Identifying Latent Classes of Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus Patients

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 392

From Childhood to Adulthood: Longitudinal Trajectory of Damage in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 785

Further Validation of Simple Index As a Simple Disease Activity Assessment Tool for SLE

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 764

Gastrointestinal Adverse Events of Azathioprine in Daily Clinical Practice: Independent of Thiopurine Methyltransferase Activity

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 417

Gender Differences in Pediatric Localized Scleroderma: Clinical and Patient-Reported Outcomes

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 711

Gender Specific Differences in Ankylosing Spondylitis at Treatment Initiation in Patients Treated with Infliximab or Golimumab

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 122

General Practitioners’ Perceptions of Methotrexate and Anti-TNF Therapies: A Qualitative Study

Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

9:00AM-11:00AM: Abstract Number: 110

Genome-Wide DNA Epigenetic Profiling of Monozygotic Twins[L1] Discordant for ACPA or ACPA-Positive Rheumatoid Arthritis Reveals Novel Associated Genes

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 566

Genome-Wide Trans-Ancestry Meta-Analysis of Herpes Zoster in RA and Pso Patients Treated with Tofacitinib

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

9:00AM-11:00AM: Abstract Number: 97

Genomic Sequencing of Uric Acid Metabolizing and Clearing Genes in Relationship to Xanthine Oxidase Inhibitor Dose

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 721

Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 754

Glutathione S Transferases (GST) Polymorphisms Are Independents Predictors of Efficacy and Toxicity in Lupus Nephritis Treated with Cyclophosphamide

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 193

Going Back to Basics – Redefining the Normal Pattern in Nailfold Capillaroscopy in a Large Healthy Population: Results of the German “Rheuma-Truck” Cohort

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 228

Gout and Risk of Non-Vertebral Osteoporotic Fracture

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 233

Gout Does Not Decrease the Risk of Parkinson’s Disease: A Systematic Review and Meta-Analysis

Metabolic and Crystal Arthropathies Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].